{"name":"Xeolas Pharmaceuticals Limited","slug":"xeolas-pharmaceuticals-limited","ticker":"","exchange":"","domain":"","description":"Xeolas Pharmaceuticals Limited is a biopharmaceutical company focused on the development of innovative treatments for unmet medical needs. The company's lead candidate, Soludronate, is currently in Phase 3 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Soludronate®","genericName":"Soludronate®","slug":"soludronate","indication":"Osteoporosis (phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"Soludronate®","genericName":"Soludronate®","slug":"soludronate","phase":"phase_3","mechanism":"Soludronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and disrupting the mevalonate pathway in osteoclasts.","indications":["Osteoporosis (phase 3 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdHU3WTBuTzlzX2FvRWE5VkZBOHJpNlVkc1BNZmNNVkVPckRrSjdOekg0YURBME1IV1JhcXZ0N1BiYmRnN3pRZ21oYmh4ZGpJLVFFNGw0aFZ1Q3U0MU9ROGh6QTROWGNYSEsxTEVFWlNqWE11MHRxOHdMbzlVYTFmdEFIRHZGNDMyX2ttcFRyVUQzZFNuLTVNTVRrVjVNbkhpM3R1cTQ3djdCUVl2TTBLSWw0S3k5RjdwektHN2ZKNlVrODdmcEhvSlZJanRBNUh0?oc=5","date":"2020-12-11","type":"pipeline","source":"The Irish Times","summary":"Plan to close Dublin pharma plant with loss of 440 jobs a ‘devastating blow’ - The Irish Times","headline":"Plan to close Dublin pharma plant with loss of 440 jobs a ‘devastating blow’","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}